Pipeline Updates: Preliminary feedback received ... the audit of the Company’s consolidated financial statements. Rani Therapeutics is a clinical-stage biotherapeutics company focused on ...

Fourth Quarter 2022 and Subsequent Highlights: Announced topline results from Phase 1 study of RT-102. In December 2022, Rani announced topline results from Part 2 (repeat-dose portion) of the ...

Rani Therapeutics Holdings ... platform and highlight the important advancements that Rani has achieved in its pipeline over the past year. Then I will share how we are leveraging the RaniPill ...

Rani Therapeutics Holdings ... a lack of independent advancements or breakthroughs in their own product pipeline. The inclusion of forward-looking statements highlights potential risks and ...

Rani Therapeutics (NASDAQ ... in the field of oral drug delivery and need for lots of cash to support the pipeline. There are 2 methods to allow oral delivery of injectables; (1) chemical methods ...

and development of our pipeline, extending our cash runway to mid-2024,” said Svai Sanford, Chief Financial Officer of Rani Therapeutics. “Looking ahead to the remainder of the year ...

Additionally, Rani Therapeutics’ interest in expanding its pipeline to include an obesity program, which is backed by encouraging preclinical studies showing comparable weight loss effects to ...

Rani Therapeutics also announced its anticipation for a Phase 1 clinical trial in 2025 for RT-114, an oral GLP-1/GLP-2 dual agonist for obesity treatment, developed in partnership with ProGen.

The firm's pipeline includes RT-114, a RaniPill capsule containing a dual-agonist for GLP-1 and GLP-2, named PG-102. Rani Therapeutics is preparing to initiate a Phase 1 trial for RT-114.

SAN JOSE, Calif., Jan. 05, 2023 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage ...